Genome Biology Group

Rolf I. Skotheim
Group leader

We investigate cancer genomes by integrated computational and laboratory based approaches. Our aim is to identify and characterise critical genes involved in the cancer development. Such genes may serve as diagnostic or prognostic biomarkers and also as targets for future molecularly tailored therapy. Our studies are mainly focused on testicular and colorectal cancer.

The group is member of a Centre of Excellence in Cancer Biomedicine and a Centre for Research-based Innovation in Cancer Stem Cells.

RESEARCH THEMES

Transcript variants in cancer from exon microarrays and deep sequencing

Testicular cancer: Tumour stem cells, etiology and effects after chemotherapy

Fusion genes: a universal detection tool and novel fusion transcripts

Group contact information

Department of Cancer Prevention, Institute for Cancer Research
Oslo University Hospital HE - Norwegian Radium Hospital
Mail address: P. O. Box 4953 Nydalen, NO-0424 Oslo, Norway
Street address: Norwegian Radium Hospital, Montebello
Phone: +47 2278 1727 / +47 2293 4000
E mail: rolf.i.skotheim(a)rr-research.no

Print this page [4691 visits]

News & events

New gene-based prognostic test for colorectal cancer
Jan 9, 2012

The Norwegian Oncology Forum’s Young Researcher award 2011 to Guro E. Lind
Nov 23, 2011

Stine Aske Danielsen successfully defends her PhD thesis
Nov 22, 2011

Andreas Hoff and Peter Eide awarded Master’s degree
Jun 28, 2011

Researchers from Department of Cancer Prevention reveal importance for transcriptome instability in colorectal cancer
May 31, 2011

More news

Latest publications

Genome Biology Group

Matheu A, Collado M, Wise C, Manterola L, Cekaite L, Tye AJ, Canamero M, Bujanda L, Schedl A, Cheah KS, Skotheim RI, Lothe RA, Lopez de Munain A, Briscoe J, Serrano M, Lovell-Badge R
Oncogenicity of the developmental transcription factor Sox9
Cancer Res (in press)
PubMed 22246670

Agesen TH, Sveen A, Merok MA, Lind GE, Nesbakken A, Skotheim RI, Lothe RA
ColoGuideEx: a robust gene classifier specific for stage II colorectal cancer prognosis
Gut (in press)
PubMed 22213796

Sveen A, Bakken AC, Agesen TH, Lind GE, Nesbakken A, Nordgård O, Brackmann S, Rognum TO, Lothe RA, Skotheim RI
The exon-level biomarker SLC39A14 has organ-confined cancer-specificity in colorectal cancer
Int J Cancer (in press)
PubMed 22173985

More publications